The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of databases, translational research programs, and clinical trials. Access to innovative strategies represents a major challenge, as there is a lack of funding for clinical research in rare cancers and their rarity precludes the design of robust clinical trials that could lead to specific approval of drugs. In this context, patient-centered initiatives, such as the establishment of dedicated networks, are warranted. International societies, such as IMIG (International Mesothelioma Interest Group) and ITMIG (International Thymic Malignancy Interest Group) provide infrastructure for global collaboration, and there are many advantages to having strong regional groups working on the same issues. There may be regional differences in risk factors, susceptibility, management and outcomes. The ability to address questions both regionally as well as globally is ideal to develop a full understanding of mesothelioma and thymic malignancies. In Europe, through the integration of national networks with EURACAN, the collaboration with academic societies and international groups, the development of networks in thoracic oncology provides multiplex integration of clinical care and research, ultimately ensuring equal access to high quality care to all patients, with the opportunity of conducting high level clinical and translational research projects.

Imbimbo, M., Maury, J., Grassino, M., Girard, N., Vitale, F. (2019). Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 45(1), 75-80 [10.1016/j.ejso.2018.01.078].

Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting

Vitale, F
Membro del Collaboration Group
2019-01-01

Abstract

The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of databases, translational research programs, and clinical trials. Access to innovative strategies represents a major challenge, as there is a lack of funding for clinical research in rare cancers and their rarity precludes the design of robust clinical trials that could lead to specific approval of drugs. In this context, patient-centered initiatives, such as the establishment of dedicated networks, are warranted. International societies, such as IMIG (International Mesothelioma Interest Group) and ITMIG (International Thymic Malignancy Interest Group) provide infrastructure for global collaboration, and there are many advantages to having strong regional groups working on the same issues. There may be regional differences in risk factors, susceptibility, management and outcomes. The ability to address questions both regionally as well as globally is ideal to develop a full understanding of mesothelioma and thymic malignancies. In Europe, through the integration of national networks with EURACAN, the collaboration with academic societies and international groups, the development of networks in thoracic oncology provides multiplex integration of clinical care and research, ultimately ensuring equal access to high quality care to all patients, with the opportunity of conducting high level clinical and translational research projects.
2019
Imbimbo, M., Maury, J., Grassino, M., Girard, N., Vitale, F. (2019). Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 45(1), 75-80 [10.1016/j.ejso.2018.01.078].
File in questo prodotto:
File Dimensione Formato  
imbimbo2018.pdf

accesso aperto

Tipologia: Post-print
Dimensione 1.23 MB
Formato Adobe PDF
1.23 MB Adobe PDF Visualizza/Apri
1-s2.0-S0748798318301148-main.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 701.38 kB
Formato Adobe PDF
701.38 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/401666
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 12
social impact